This is a low-risk undertaking by VRTX/JNJ. Assuming that patient compliance is strong (as it ought to be in an open-label clinical setting where there are no superfluous placebo pills), the only underlying scientific issue is the PK profile of Telaprevir, which by now is well understood. With a typical non-inferiority margin for this kind of study, the likelihood of a non-inferiority finding is very high, IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.